Database grows for genetic tests
This article was originally published in The Gray Sheet
Sixteen new genetic tests for diagnosis, prognosis and monitoring of non-cancer diseases and conditions are identified in a Dec. 9 draft technology assessment released by the Agency for Healthcare Research and Quality. According to the draft, the report aims to identify genetic tests for non-cancer conditions that are already in clinical practice and applicable to the Medicare population, as well as create one-page summaries on each test for a public electronic database that will separately include information on genetic tests for cancers. The tech assessment describes eight pharmacogenetic tests for non-cancer conditions - such as for warfarin dosing and sensitivity, and clopidogrel non-responsiveness - and eight tests for genetic disease association, including those that identify risk for psoriasis arthritis, heart disease and periodontal disease. AHRQ will take comments through Jan. 8, 2010
You may also be interested in...
Asking whether FDA’s decision to allow emergency use of two old anti-malarial drugs was ‘political’ misses the point. The issue already was political, and FDA’s action may well be the best way to keep some measure of federal control on supplies of a drug with important other uses.
Guidelines for health care providers could help prevent shortages as demand for possible treatments surge, groups say. Stakeholders also argue “Buy America” executive order would hamper drug access.
BD and BioMedomics have released a new rapid point-of-care test that can detect antibodies in blood to confirm current or past exposure to COVID-19.